NCT03570892 2026-04-08
BELINDA
Novartis
Phase 3 Completed
Clinical Trials
10 trialsNCT01516580 2026-02-09
Intergroup Randomized Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Rituximab Evaluation in High Risk Patients
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3 Completed
NCT01855750 2025-02-04
A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma
Janssen Research & Development, LLC
Phase 3 Completed
NCT02787239 2022-05-09
Clinical Study to Compare the Efficacy and Safety of Rituximab Biosimilar HLX01 and Rituximab in Combination With CHOP, in Previously Untreated Subjects With CD20+ DLBCL
Shanghai Henlius Biotech
Phase 3 Completed
NCT00329030 2021-11-01
BMTCTN0401
National Heart, Lung, and Blood Institute (NHLBI)
Phase 3 Completed
NCT00790036 2017-07-12
PILLAR2
Novartis
Phase 3 Completed
NCT00854568 2014-08-20
Comparison Study of Doxorubicin Versus Epirubicin-induced Cardiotoxicity in Patients With DLBCL
Fudan University
Phase 3 Completed
NCT00312845 2012-06-25
Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
Millennium Pharmaceuticals, Inc.
Phase 3 Completed
NCT00162656 2012-03-28
Treatment of Mature B-cell Lymphoma/Leukaemia
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3 Completed
NCT00168740 2005-09-15
Treatment of Relapsed Low-Grade or Follicular Lymphoma With Rituximab (Also Known as Rituxan, IDEC-C2B8, IDEC-102)
Biogen
Phase 3 Completed